ArticleDiabetologia2017
Melatonin signalling and type 2 diabetes risk: too little, too much or just right?
Article in Diabetologia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Interplay of Dinner Timing and MTNR1B Type 2 Diabetes Risk Variant on Glucose Tolerance and Insulin Secretion: A Randomized Crossover Trial.Diabetes care · 2022Trial
- Nocturnal melatonin secretion and risk of type 2 diabetes: a prospective cohort study.The Journal of clinical endocrinology and metabolism · 2026Article
- The melatonin receptor 1B gene links circadian rhythms and type 2 diabetes mellitus: an evolutionary story.Annals of medicine · 2023Review
- Membrane Melatonin Receptors Activated Cell Signaling in Physiology and Disease.International journal of molecular sciences · 2021Review
- Insights into pancreatic islet cell dysfunction from type 2 diabetes mellitus genetics.Nature reviews. Endocrinology · 2020Review
- Melatonin Effects on Glucose Metabolism: Time To Unlock the Controversy.Trends in endocrinology and metabolism: TEM · 2020Review
- Circadian, Sleep and Caloric Intake Phenotyping in Type 2 Diabetes Patients With Rare Melatonin Receptor 2 Mutations and Controls: A Pilot Study.Frontiers in physiology · 2020Article
- Melatonin in type 2 diabetes mellitus and obesity.Nature reviews. Endocrinology · 2019Review
- Updated View on the Relation of the Pineal Gland to Autism Spectrum Disorders.Frontiers in endocrinology · 2019Article
- Melatonin Uptake by Cells: An Answer to Its Relationship with Glucose?Molecules (Basel, Switzerland) · 2018Review
- Melatonin receptors: molecular pharmacology and signalling in the context of system bias.British journal of pharmacology · 2018Review
- Human Genetics of Obesity and Type 2 Diabetes Mellitus: Past, Present, and Future.Circulation. Genomic and precision medicine · 2018Review
- Melatonin attenuates smoking-induced hyperglycemia via preserving insulin secretion and hepatic glycogen synthesis in rats.Journal of pineal research · 2018Article
- Disentangling the Role of Melatonin and its Receptor MTNR1B in Type 2 Diabetes: Still a Long Way to Go?Current diabetes reports · 2017Review
- Genetic aetiology of glycaemic traits: approaches and insights.Human molecular genetics · 2017Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Of the associations of genetic variants with type 2 diabetes, the one of an SNP in an intron of the gene encoding the melatonin receptor 1B (MTNR1B) has been remarkably robust. Work from our group and others has provided support for a model where carriers of this risk G allele exhibit increased MTNR1B expression in islets of Langerhans. Most published studies to date favour that melatonin's action on the beta cell is inhibition of insulin secretion. Hence, our model proposes that this inhibitory effect of melatonin is exaggerated in carriers of the MTNR1B risk G allele. This would explain why this genetic association causes reduced insulin secretion and greater risk of future type 2 diabetes, as has been observed in numerous studies. Concurrently, another body of work has shown that rare MTNR1B alleles, which could perturb receptor function, also associate with type 2 diabetes. In this commentary, it is suggested that such apparently conflicting observations can be reconciled by the fact that non-coding (intronic; frequent) and coding (exonic; rare) alleles of MTNR1B give rise to different phenotypes. Thus, altered gene transcription may explain why SNPs, which do not alter coding sequences, exhibit cell-specific effects. In contrast, SNPs that change protein sequences are more likely to exert generalised effects since an altered protein will appear in all cells expressing the gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.